Scientists at The Pirbright Institute have used genetic engineering to develop a more efficient and effective vaccine for Marek’s disease which could pave the way for a new generation of poultry disease vaccines.
The Pirbright Institute is one of the largest recipients of the Government’s new £120 million fund to fight deadly diseases – winning £1.580 million with its partners, for a joint project to develop a safe and effective livestock vaccine against Rift Valley fever.
Studies assessing the effectiveness of anti-viral treatments for swine flu and those seeking to understand the behaviour of the virus, must factor in the route of infection during experiments, as this has a greater impact on results than previously thought, a new study from The Pirbright Institute has found.
Influenza A virus (IAV) is a global health threat. The infection in pigs causes severe disease when combined with other respiratory pathogens, and can result in considerable economic losses to farmers, and poses a significant risk to humans too.
Scientists at The Pirbright Institute have been encouraged by the results from a potential new vaccine candidate against Marek’s disease (MD). Using a recombinant (new combinations of genetic material) adenovirus which carries a single gene from a virulent strain of Marek’s disease virus, they are hopeful that further research and trials could lead to the production of an effective MD vaccine that is cheaper and easier to produce - and crucially has no possibility of reverting to a virulent strain.
The full potential of genetic modification or GM technology to tackle some of the world’s most dangerous diseases is still not being realised well over a decade after it was first developed. The lack of effective international regulation, regional variations in public opinion and uncertainties about the long-term effects are all hindering progress, say scientists from The Pirbright Institute, in a new discussion paper.
A large delegation from The Pirbright Institute will be flying the flag for great British science this week, at the biggest ever entomology conference.
Researchers at The Pirbright Institute have developed a field test to diagnose African horse sickness, which is reliable, fast and simple to use.
African horse sickness (AHS) is a viral disease that infects all equine species and is often fatal in horses and mules. It has become economically significant within the last century; with outbreaks impacting on the Iberian and Arabian Peninsula, the Middle East, the Indian subcontinent and North Africa.
Scientists discover maleness gene in malaria mosquitoes, opening the way for genetic control of the disease
Scientists, led by Dr Jaroslaw Krzywinski, Head of the Vector Molecular Biology group at The Pirbright Institute have isolated a gene, which determines maleness in the species of mosquito that is responsible for transmitting malaria.
Scientists at The Pirbright Institute are confident they have identified a safe and effective vaccination strategy for African horse sickness virus (AHSV) – the battle is now to build a business case persuasive enough to encourage a manufacturer to develop it and finally bring it to market.
The Pirbright Institute has signed an international partnership agreement with IZSLER(1), the leading Italian animal disease research body, to jointly produce cutting edge diagnostic kits for foot-and-mouth disease (FMD).